No Data
No Data
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Regeneron Gains 13.5% Year to Date: How to Play the Stock?
Regeneron Sees $56M Pretax Charge Hitting 3Q Earnings
Regeneron Sees IPR&D Impact of About $0.43/share on Q3 Income
Express News | Regeneron Pharmaceuticals - Expects Q3 Results Will Include Acquired Ipr&D Charge of Sbout $56 Mln on Pre-Tax Basis